Order Article Reprints

Evrard C, Aparicio T, Soularue E, Le Malicot K, Desramé J, Botsen D, El Hajbi F, Gonzalez D, Lepage C, Bouché O, et al. Safety of FOLFIRI + Durvalumab +/− Tremelimumab in Second Line of Patients with Advanced Gastric Cancer: A Safety Run-In from the Randomized Phase II Study DURIGAST PRODIGE 59. Biomedicines. 2022; 10(5):1211. https://doi.org/10.3390/biomedicines10051211

Evrard, Camille, Thomas Aparicio, Emilie Soularue, Karine Le Malicot, Jérôme Desramé, Damien Botsen, Farid El Hajbi, Daniel Gonzalez, Come Lepage, Olivier Bouché, and et al. 2022. "Safety of FOLFIRI + Durvalumab +/− Tremelimumab in Second Line of Patients with Advanced Gastric Cancer: A Safety Run-In from the Randomized Phase II Study DURIGAST PRODIGE 59" Biomedicines 10, no. 5: 1211. https://doi.org/10.3390/biomedicines10051211

Evrard, C., Aparicio, T., Soularue, E., Le Malicot, K., Desramé, J., Botsen, D., El Hajbi, F., Gonzalez, D., Lepage, C., Bouché, O., Tougeron, D., & on behalf of the DURIGAST—PRODIGE 59 Investigators/Collaborators. (2022). Safety of FOLFIRI + Durvalumab +/− Tremelimumab in Second Line of Patients with Advanced Gastric Cancer: A Safety Run-In from the Randomized Phase II Study DURIGAST PRODIGE 59. Biomedicines, 10(5), 1211. https://doi.org/10.3390/biomedicines10051211